Blood Plasma Thawing Device Market was valued at USD 215.0 million in 2021 and is expanded to grow at a significant CAGR of 11.4% over 2022-2028. The process of allowing frozen plasma to stand at a temperature above zero degrees Celsius is known as plasma thawing. The plasma unit is kept dry by the plasma thawing mechanism. The rise of industry players is projected to be aided by an increase in demand for manual and automated blood thawing systems from hospitals, blood banks, and transfusion medicine centers. Furthermore, a strong preference for dry plasma thawers is projected to boost demand in the coming years. Innovations in thawing methods to boost the safety and effectiveness of transfusion practices, propelling the blood thawing system market. Increased prevalence of chronic disease, which drives demand for blood and plasma products, increased launches and agreements, and technical improvements to make the thawing process easier and simpler are the primary factors driving the market growth. Sales of blood thawing systems are projected to increase in the near future as prominent manufacturers begin to incorporate cutting-edge technologies. Dry plasma thawing products are gaining preference over traditional water baths or wet plasma thawers, as they help increase the success of transfusion of adult stem cells. The industry value for blood thawing systems is expected to rise due to increased demand from major end-use sectors and prominent manufacturers’ flurry of new inventions. Increased demand for automated biomedical warming and thawing devices is also helping to drive market growth. Growing demand for pharmaceutical research is further poised to increase the adoption rate for biomedical warming and thawing devices, thereby fuelling the market progression during the forecast timeframe. According to forecasts, the blood/plasma thawing device market is dominated by the blood banks segment. Major drivers driving the expansion of this end-user segment include an increase in the number of blood banks, as well as improved accessibility and availability of blood samples in blood banks.
Recent Market Developments:
In December 2021, Sartorius and HOF Sonderanlagenbau, announced a partnership to integrate two HOF horizontal plate freeze-thaw units into Sartorius’ portfolio offering customers a full suite of compatible freeze-thaw equipment and consumables. This partnership will enable faster and easier implementation of robust frozen drug substance management platforms through improved validation and purchase support from a single supplier.
In March 2021,Cardinal Health announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working capital accounts. The transaction is expected to close in the first half of Cardinal Health’s fiscal year 2022, subject to customary closing conditions and regulatory clearances.